This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BD (BDX) Launches PAXgene in Europe for Advanced DNA Testing
by Zacks Equity Research
Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.
NuVasive's SpineTRACK Registry Gains New CMS Designation
by Zacks Equity Research
NuVasive's (NUVA) receipt of the QCDR designation for its SpineTRACK buoys optimism for the stock. This achievement might add value to cushion its efforts to provide systems-based spine solutions.
Luminex (LMNX) Banks on Solid Product Line, Competition Rife
by Zacks Equity Research
Luminex's (LMNX) extensive product line and rising revenues raise optimism. However, a challenging reimbursement scenario is likely to mar prospects.
Abiomed's Extended FDA Nod for Impella Refines PCI Diagnosis
by Zacks Equity Research
Abiomed (ABMD) gets second FDA PMA for its flagship Impella in a row, with a view to treating patients with High Risk PCI.
Haemonetics (HAE) Banks on Plasma Franchise, Competition Rife
by Zacks Equity Research
Haemonetics' (HAE) strong end-market demand for plasma-derived biopharmaceuticals continues to drive growth.
Haemonetics (HAE) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Haemonetics (HAE) gains from promising financial results in the third quarter of fiscal 2018.
Is Surprise Coming for Haemonetics (HAE) This Earnings Season?
by Zacks Equity Research
Is Surprise Coming for Haemonetics (HAE) This Earnings Season?
Haemonetics Banks on Hospital Business, Competition Rife
by Zacks Equity Research
For fiscal 2018, Haemonetics (HAE) expects the Hospital business to grow 7-10%.
Haemonetics (HAE) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Haemonetics (HAE) focuses on development and launch of NexSys PCS plasmapheresis system.
Haemonetics (HAE) Grows on Strong Plasma, Competition Rife
by Zacks Equity Research
Despite stiff competition, Haemonetics (HAE) grows on the back of its Plasma and Haemonetics Management franchises.
Haemonetics (HAE) in Focus: Stock Moves 10% Higher
by Zacks Equity Research
Haemonetics (HAE) saw its shares rise nearly 10% on the day after the company reported better-than-expected second quarter and first Half Fiscal 2018 results.
Haemonetics Grows on Strong Plasma, Blood Center Sluggish
by Zacks Equity Research
Haemonetics' (HAE) encouraging growth in both Plasma and Haemonetics Management franchises keeps the market upbeat. However, slow revenue growth at the Blood Center franchise raises concern.
Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish
by Zacks Equity Research
Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.
Cardiovascular Systems Unveils Favorable LIBERTY 360 Data
by Zacks Equity Research
LIBERTY 360 Study shows the importance of endovascular intervention in patients with Critical Limb Ischemia (CLI) to prevent amputation.
Zacks.com featured highlights: The Chemours Company, Haemonetics Corporation and The Brink's Company
by Zacks Equity Research
Zacks.com featured highlights: The Chemours Company, Haemonetics Corporation and The Brink's Company
3 Best Stocks with Upgraded Broker Ratings to Invest In Now
by Zacks Equity Research
Selecting stocks from the vast investment universe is not an easy task. In such a situation, sound broker advice helps to pick the right stocks.
Haemonetics Banks on Solid Plasma & Haemonetics Management
by Zacks Equity Research
Despite encouraging growth at the Plasma and Haemonetics Management franchises, the underperformance at the BloodCenter franchisee was quite a dampener for Haemonetics (HAE).
Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Haemonetics (HAE) rides high on Plasma and Haemonetics Management franchises strength in Q1.
Why Earnings Season Could Be Great for Haemonetics (HAE)
by Zacks Equity Research
Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
Can PerkinElmer (PKI) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
Despite an upbeat outlook, volatility in the foreign exchange rate is likely to mar PerkinElmer's (PKI) results in the second quarter.
Haemonetics Plasma Arm Advances, Blood Center Sluggish
by Zacks Equity Research
On Jul 13, we issued an updated research report on Haemonetics Corporation (HAE).
Haemonetics Rides on Solid Plasma, Slows Blood Center Growth
by Zacks Equity Research
On Jun 13, we issued an updated research report on Haemonetics Corporation (HAE).
Haemonetics (HAE) Down 2.2% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View
by Zacks Equity Research
Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 5.4% year over year.
Haemonetics' Plasma Group Strong, Blood Center Group a Drag
by Zacks Equity Research
On Apr 11, we issued an updated research report on Braintree, MA-based Haemonetics Corporation (HAE), a leading provider of blood management solutions.